Inventiva Announces Schedule for Publication and Presentation of 2021 and 2022 Financial Results
Inventiva, a biopharmaceutical company focused on the development of treatments for non-alcoholic steatohepatitis (NASH) and other diseases, recently announced its schedule for the publication and presentation of its 2021 and 2022 financial results. The company plans to publish its 2021 financial results on April 28, 2021, and its 2022 financial results on April 27, 2022.
About Inventiva
Inventiva is a biopharmaceutical company focused on the development of treatments for NASH and other diseases. The company is headquartered in Paris, France, and has offices in the United States, the United Kingdom, and Germany. Inventiva is listed on the Euronext Paris stock exchange and is a component of the CAC Small and CAC Mid & Small indices.
Inventiva’s Pipeline
Inventiva is currently developing a pipeline of treatments for NASH and other diseases. The company’s lead product candidate is lanifibranor, a once-daily oral therapy for NASH. Lanifibranor is currently in Phase 3 clinical trials and is expected to be submitted for regulatory approval in the United States and Europe in 2021. In addition, Inventiva is developing a pipeline of other treatments for NASH, including a combination therapy of lanifibranor and cenicriviroc, and a novel oral therapy for NASH.
Inventiva’s Financial Results
Inventiva plans to publish its 2021 financial results on April 28, 2021. The company expects to report a net loss for the year, primarily due to research and development expenses related to its pipeline of treatments for NASH and other diseases. In addition, Inventiva plans to publish its 2022 financial results on April 27, 2022.
Inventiva’s Presentations
In addition to publishing its financial results, Inventiva plans to present its 2021 and 2022 financial results at several investor conferences. The company plans to present its 2021 financial results at the Jefferies Virtual Healthcare Conference on May 18, 2021, and at the UBS Global Healthcare Conference on May 25, 2021. In addition, Inventiva plans to present its 2022 financial results at the Jefferies Virtual Healthcare Conference on May 17, 2022, and at the UBS Global Healthcare Conference on May 24, 2022.
Inventiva’s Outlook
Inventiva is focused on the development of treatments for NASH and other diseases. The company is currently in Phase 3 clinical trials with its lead product candidate, lanifibranor, and is expecting to submit the drug for regulatory approval in 2021. In addition, Inventiva plans to publish its 2021 and 2022 financial results and present them at several investor conferences. With its pipeline of treatments and its plans for financial disclosure, Inventiva is well-positioned to continue its growth in the coming years.